Clinical Trial Finder

Key

Inclusion Criteria:

• - Participant and/or parent/legal guardian must be able to understand and provide informed consent and/or assent, as applicable.

• - Male or female, 12 to less than 56 years of age at screening.

• - Allergic to at least 1 of the following foods: peanut, milk, egg, cashew, or walnut, as confirmed by the following criteria: - a.

For participants aged 12 to <18 years:

• - i.

Allergic to peanut: participant must meet all criteria below:

• - 1.

Positive SPT (≥4 mm wheal greater than saline control) to peanut.

• - 2.

Positive peanut IgE (≥6 kUA/L) at screening or within 3 months of screening.

• - 3.

Positive blinded oral food challenge (OFC) to peanut during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤100 mg (ie, cumulative dose of ≤144 mg) of peanut protein.

• - ii.

Allergic to milk or egg: unable to tolerate both cooked and uncooked forms:

• - 1.

Positive SPT (≥4 mm wheal greater than saline control) to the specific food.

• - 2.

Positive food-specific IgE (≥6 kUA/L) at screening or within 3 months of screening.

• - 3.

Positive blinded OFC to the specific food during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg (ie, cumulative dose of ≤444 mg) of food protein.

• - iii.

Allergic to cashew: participant must meet all criteria below:

• - 1.

Positive SPT (≥4 mm wheal greater than saline control) to cashew. OR.

• - 2.

Positive cashew IgE (≥6 kUA/L) at screening or within 3 months of screening. AND.

• - 3.

Positive blinded OFC to cashew during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤100 mg (ie, cumulative dose of ≤144 mg) of cashew protein.

• - iv.

Allergic to walnut: participant must meet all criteria below:

• - 1.

Positive SPT (≥4 mm wheal greater than saline control) to walnut. OR.

• - 2.

Positive walnut IgE (≥6 kUA/L) at screening or within 3 months of screening AND.

• - 3.

Positive blinded OFC to walnut during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg (ie, cumulative dose of ≤444 mg) of walnut protein.

• - b.

For participants aged 18 to <56 years:

• - i.

Allergic to peanut or cashew: participant must meet all of the following criteria:

• - 1.

Positive SPT (≥3 mm wheal greater than saline control) to peanut or cashew.

• - 2.

Positive peanut or cashew IgE (≥0.35 kUA/L) at screening or within 3 months of screening.

• - 3.

Positive blinded OFC to peanut or cashew during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤100 mg (ie, cumulative dose of ≤144 mg) of peanut or cashew protein.

• - ii.

Allergic to milk or egg: participant must meet all of the following criteria:

• - 1.

Positive SPT (≥3 mm wheal greater than saline control) to the specific food.

• - 2.

Positive food-specific IgE (≥0.35 kUA/L) at screening or within 3 months of screening.

• - 3.

Positive blinded OFC to the specific food during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg (ie, cumulative dose of ≤444 mg) of food protein.

• - iii.

Allergic to walnut: participant must meet all of the following criteria:

• - 1.

Positive SPT (≥3 mm wheal greater than saline control) to walnut.

• - 2.

Positive walnut IgE (≥0.35 kUA/L) at screening or within 3 months of screening.

• - 3.

Positive blinded OFC to walnut during the screening DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg (ie cumulative dose of ≤444 mg) of walnut protein.

• - With body weight (as measured at screening) and total serum IgE level (as measured within 3 months of screening) suitable for RPT904 dosing (per RPT904 dosing table).

• - Female Participants: - 1.

Must not be pregnant or breastfeeding.

• - 2.

Women of non-childbearing potential (e.g., surgically sterile or postmenopausal) are eligible.

• - 3.

Women of childbearing potential must have a negative pregnancy test before starting study treatment, agree to use a protocol-defined method of contraception during the study and for at least 10 months after the last dose, and must not donate eggs or undergo egg retrieval during this period.

• - Male Participants: - 1.

Must agree to either remain abstinent from heterosexual intercourse (if that is their usual lifestyle) or use protocol-defined contraception during the study and for 10 months after the last dose.

• - 2.

Must not donate semen or participate in sperm banking during this time, and if they have a female partner of childbearing potential, she should also use effective contraception.

Exclusion Criteria:

• - Clinically significant lab abnormalities at screening.

• - Sensitivity or suspected/known allergy to any component of the active or placebo OFC material (excluding the test allergens peanut, milk, egg, walnut, and cashew being tested), or drugs related to RPT904 (eg, monoclonal antibodies, polyclonal gamma globulin).

• - Uncontrolled or severe asthma/wheezing at screening.

• - Current use of oral, IM, or IV corticosteroids, tricyclic antidepressants, or β-blockers (oral or topical).

• - Past or current immunotherapy to any study foods within 6 months of screening.

• - Treatment with immunomodulatory therapy within 6 months of screening.

• - Currently in the "build-up phase" of inhalant allergen immunotherapy (i.e., not yet on maintenance).

Note: individuals on stable maintenance dosing may be eligible.

• - Past or current medical problems (eg, severe latex allergy), chronic diseases (other than asthma/wheezing, atopic dermatitis, or rhinitis) requiring therapy (eg, heart disease, diabetes), abnormal physical findings or lab results not listed above that, in the Principal Investigator's opinion, may increase study related risks, hinder protocol compliance, or impact data quality or interpretation .

Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Arms

Experimental: RPT904 (Q8W)

RPT904 every 8 weeks. The dose levels of RPT904 (150 mg, 300 mg, and 600 mg) within the Q8W cohort will be assigned based on participant weight and baseline total IgE level. RPT904 subcutaneous injection every 8 weeks with a loading dose at Week 2 (Part 1: 24 weeks; Part 2: 24 weeks); matching placebo at intervening visits to maintain blinding.

Experimental: RPT904 (Q12W)

RPT904 every 12 weeks. The dose levels of RPT904 (150 mg, 300 mg, and 600 mg) will be assigned based on participant weight and baseline total IgE level. RPT904 subcutaneous injection every 12 weeks with a loading dose at Week 2 (Part 1: 24 weeks; Part 2: 24 weeks); matching placebo at intervening visits to maintain blinding.

Placebo Comparator: Placebo

Placebo subcutaneous injection on schedules matching both the Q8W and Q12W arms in Part 1 (24 weeks); RPT904 every 8 or 12 weeks with a loading dose at Week 26 on schedules matching both the Q8W and Q12W arms Part 2 (24 weeks), with matching placebo at intervening visits to maintain blinding.

Interventions

Drug: - RPT904

Subcutaneous injection once every 8 weeks

Drug: - RPT904

Subcutaneous injection once every 12 weeks

Other: - Placebo

Subcutaneous injection at the intervening dosing visits

Drug: - RPT904

Subcutaneous injection once every 8 weeks (Part 2)

Drug: - RPT904

Subcutaneous injection once every 12 weeks (Part 2)

Other: - Placebo

Subcutaneous injection on schedules matching both the Q8W and Q12W arms (Part 1). Subcutaneous injection at the intervening dosing visits (Part 2)